1. Home
  2. EVAX vs MDXH Comparison

EVAX vs MDXH Comparison

Compare EVAX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$2.94

Market Cap

23.6M

Sector

Health Care

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.46

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVAX
MDXH
Founded
2008
2003
Country
Denmark
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
21.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
EVAX
MDXH
Price
$2.94
$0.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$11.67
$7.67
AVG Volume (30 Days)
12.0K
266.4K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
$328.20
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.52
$0.40
52 Week High
$12.15
$5.33

Technical Indicators

Market Signals
Indicator
EVAX
MDXH
Relative Strength Index (RSI) 46.42 42.38
Support Level $2.97 $0.40
Resistance Level $3.61 $3.79
Average True Range (ATR) 0.13 0.02
MACD 0.03 0.02
Stochastic Oscillator 59.21 63.50

Price Performance

Historical Comparison
EVAX
MDXH

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: